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Objectives:  There  is a renewed  interest  in  health  system  indicators.  In 1976  a measure  of  quality  of
healthcare,  amenable  mortality,  was  introduced  by Rutstein.  This  indicator  is based  on the concept  that
deaths  from  certain  causes  should  not  occur  in  the  presence  of  timely  and  effective  healthcare.  In  the
project  “Amenable  mortality  in  the European  Union:  toward  better  indicators  for  the  effectiveness  of
health systems”  (AMIEHS),  we  introduce  a new  approach  to  the selection  of  indicators  of  amenable
mortality.
Methods:  Based  on  predeﬁned  selection  criteria  and  a  broad  review  of  the literature  on  the  effectiveness
of  medical  interventions,  a  ﬁrst  set of  potential  indicators  of  amenable  mortality  (causes  of death)  was
selected.  The  timing  of the  introduction  of medical  innovations  was  established  through  reviews  and
questionnaires  sent  to national  experts  from  seven  participating  European  countries.  The  preselected
indicators  were  then  validated  by a trend  analysis  that identiﬁed  associations  between  the timing  of
innovations  and  cause-speciﬁc  mortality  trends  and  by  a Delphi-procedure.
Results:  After  a short  review  of  previous  lists  of  amenable  mortality  indicators  and a  detailed  description
of  the  innovative  procedure  in  the  AMIEHS  project  we  present  a list of 14 causes  of  death  that  passed  our
selection  criteria.  We  illustrate  our  empirical  validation  of these  indicators  using  the examples  of  peptic
ulcer  and  renal  failure.
Conclusions:  The  innovation  developed  in  the  AMIEHS  study  is  a rigorous  new  approach  to  the  concept
of  amenable  mortality  that  includes  empirical  validation.  Only  validated  indicators  can  be  successfully
used  to assess  the  quality  of  healthcare  systems  in  international  comparisons.
©  2012  SESPAS.  Published  by Elsevier  España,  S.L.  All rights  reserved.
Mortalidad  tratable  revisada:  el  estudio  AMIEHS
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Objetivos:  Actualmente  hay  un  renovado  interés  por  los  indicadores  para  los sistemas  de  salud.  En  1976,
Rutstein  propuso  la «mortalidad  tratable»  como  una  medida  de la calidad  de la atención  en salud,  par-
tiendo  de  que  ciertas  causas  de  muerte  no deben  presentarse  si  se cuenta  con  atención  médica  oportuna  y
eﬁcaz.  Un  nuevo  enfoque  se presenta  en  el  proyecto  «Mortalidad  tratable  en  la  Unión  Europea:  en  procura
de  mejores  indicadores  para  los  sistemas  de  salud»  (AMIEHS,  por  sus  siglas  en inglés)  para  seleccionar
indicadores  de  mortalidad  tratable.
Métodos:  Basándose  en  criterios  predeﬁnidos  y en  una  extensa  revisión  de  la  literatura  sobre  la  efectividad
de las  intervenciones  médicas,  se seleccionó  un primer  conjunto  de  indicadores  potenciales  de  mortalidad
tratable  (causas  de  muerte).  El momento  de  la introducción  de  las  innovaciones  médicas  se ﬁjó  mediante
revisiones  y  cuestionarios  enviados  a expertos  de  siete  países  europeos  participantes.  Se validaron  los
indicadores  preseleccionados  identiﬁcando  la asociación  entre  la  introducción  de  las innovaciones  y el
análisis  de  tendencias  para  causas  de  muerte  especíﬁcas  y  usando  un  Delphi.
Resultados:  Tras  revisar  anteriores  listas  de indicadores  de  mortalidad  tratable  y describir  el
procedimiento  innovador  en  el proyecto  AMIEHS,  presentamos  una  lista  de  14 causas  de  muerte  que
cumplen  los  criterios  de  selección.  Luego  ilustramos  nuestra  validación  empírica  usando  como  ejemplos
la  úlcera  péptica  y la insuﬁciencia  renal.
Conclusiones:  La innovación  del  estudio  AMIEHS  es  una  aproximación  rigurosa  a la  nueva  concepción  de
la mortalidad  tratable  que  incluye  validación  empírica.  Para  evaluar  la  calidad  de  los  sistemas  de  salud
en comparación  con  otros  países  sólo pueden  usarse  con  éxito  indicadores  validados.
©  2012  SESPAS.  Publicado  por Elsevier  España,  S.L.  Todos  los  derechos  reservados.
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Introduction
The introduction of new pharmaceuticals and treatment meth-
ods during the late 20th century, and new and more effective ways
of organizing care, mean that health care now contributes demon-
strably to improved population health.1,2 However, as national
health spending has tended to outstrip economic growth in most
OECD countries in recent years, reaching 9% of GDP on average,3 it is
important to quantify what this additional spending has achieved.
The World Health Report 2000 identiﬁed health gain as a funda-
mental goal of health systems4 but was unable to assess the speciﬁc
contribution of health care. It also stimulated an increasing inter-
est in performance of health systems with improved tools being
sought avidly by policy-makers seeking to determine whether they
are getting value for money in health care systems.
In the early 1970s Rutstein introduced the concept of mortality
amenable to medical care. His working group selected over 90 con-
ditions as “sentinel health events” from which disease, disability
or death “should not occur in the presence of timely and effective
care”.5 In 1977 and 1980, revisions of this list were undertaken.6,7
They have formed the basis for practically all subsequent stud-
ies on amenable mortality. Charlton was the ﬁrst to apply the
concept at the population level in England and Wales in 1974-
78, also introducing the terms “avoidable deaths” and “conditions
amenable to medical intervention”.8 He narrowed the concept by
excluding deaths that were not directly linked to medical care, e.g.
deaths avoided by policies on tobacco control. The concept was
developed further within the Health Services Research Program of
the European Community in the 1980s. This collaborative action
resulted in a European Community atlas of avoidable mortality in
which the work of Charlton and colleagues was extended and the
boundaries of health services were interpreted as encompassing
primary care, hospital care and collective health services.9 In 2001
Tobias and Jackson produced an updated list of conditions derived
from an expert consensus exercise in which the relative avoidabil-
ity of death was distributed according to primary, secondary and
tertiary actions.10
Although the concept underpinning amenable mortality has
been widely accepted since its ﬁrst introduction by Rutstein, it
has also been criticized,11,12 mostly on the basis that the relation
between health care interventions and amenable mortality has not
been tested empirically. Critics argue that for amenable mortal-
ity to be established as a valid indicator of the outcome of health
care, direct analyses of its effect on mortality are needed. This has
been addressed in the existing literature by two  means; ﬁrst, in
time series analyses, based on the implicit assumption that inno-
vations in health care affect the trend in mortality and, second,
geographically, by comparing mortality in regions with different
levels of health care. Time series analyses show faster decline in
mortality in recent decades from most of the conditions identiﬁed
as amenable compared to non-amenable.13–15 This has been used
to support the argument that at least part of the overall mortality
decline is due to improvements in health care. Two  studies of geo-
graphical variation also found mortality differences for amenable
conditions correlated with availability of corresponding health care
interventions among countries16 and regions.8 Table 1 presents a
summary of the progressive reﬁnement of conditions amenable to
health care.
Previous research applying amenable mortality to health sys-
tem comparisons have differed in their choice of indicators (e.g.
Rutstein, Charlton or Holland, sometimes with adaptations). They
have also varied in how they deﬁne “health care”. Finally, different
upper age limits are used to deﬁne which deaths are considered
amenable, which is justiﬁed because medical conditions may  be
amenable up to different ages, but which may  also introduce a bias
if different studies use different age limits. It has been noted that
Table 1
Overview of studies with distinct lists of indicators of amenable mortality.
Author Deﬁnition, selection method Number of conditions Age limit Scope of health care
Rutstein, 19765 Sentinel health
events = unnecessary disease,
unnecessary disability and
unnecessary untimely deaths
(based on expert opinions)
> 90 conditions as sentinel health
events
65 years Prevention and medical
interventions
Charlton et al., 19838 Based on Rutstein et al. (modiﬁed) 14 disease groups 65 for some
conditions
No interventions outside the scope
of  health care
Poikolainen and Eskola,
198615, 198826
Based on Rutstein (modiﬁed) > 70 amenable and 20 partly
amenable conditions
Age limit for all
conditions, 65 for
some
Causes of death amenable to health
services
Excludes conditions outside the
scope of health care
European Community Atlas
(Holland), 19889, 1993,
1997
Based on Charlton et al. and
Poikolainen and Eskola (modiﬁed)
1st edition 17 disease groups;
2nd edition extended by 8
conditions where role of health
services is less certain
3rd edition combination of causes
from previous editions
Age limit for all
conditions; in the
last edition 65 for
some conditions
Health care interventions and
national health policies
Mackenbach et al., 198813 Based on Rutstein et al. (modiﬁed) Same as in EC-Atlas project 75 years Health care interventions
Westerling, 199227,
199328, 199629
Based on Rutstein et al. and the
EC-Atlas (modiﬁed)
21 causes of death 65 years Preventable and treatable causes
Simonato, 199830 Based on Charlton et al. and the
EC-Atlas (modiﬁed) plus additional
causes
23 causes of death 65 years Causes of death amenable to
primary prevention, early
detection and treatment, and
improved treatment and medical
care
Tobias  and Jackson, 200110 Based on Charlton et al; literature
review
56 conditions 75 years Causes of death amenable to
therapeutic interventions or
responsive to individual and
population based preventive
interventions
Niti  and Ng, 200131 Based on EC-Atlas 16 64 years Medical care and primary
preventive policy measures
McKee  and Nolte, 200432 Based on Mackenbach et al.
and Charlton et al.
34 conditions 75 years Treatable and preventable
conditions
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First selection of indicators that are potentially amenable taking into account
progress in health care since the 1980s and rising life expectancy:
             • Establish and apply selection criteria on mortality data UK 1979-2000
             • Literature review on interventions
Determine the timing of innovations that might have reduced amenable
mortality in seven participating countries by
        • Reviewing the literature on introduction of innovations
        • Collecting data from participating countries
Harmonized mortality database for seven participating countries
1970-2005
Validation of amenable mortality indicators through
Mortality trend analyses
Association analysis between year of medical innovation and year of
favorable change in mortality
Delphi procedure to reach expert consensus on indicators
Interactive electronic atlas to disseminate results
Identification of discontinuities attributable to ICD coding changes
and death registration and development of correction factors
Figure 1. Structure of the AMIEHS project.
the lack of explicit criteria for selecting indicators of amenable
mortality is an important shortcoming of the existing
literature.12,14 The knowledge on indicators of amenable mortality
is insufﬁcient to believe that amenable mortality can serve as
an indicator for the quality of health care because hardly any
validation is done to reveal an empirical relation between the
quality of health care and mortality outcome.
In the following method section we describe a systematic
approach to select indicators of amenable mortality including an
explicit list of initial selection criteria. We  deﬁne health care as pri-
mary care, hospital care and personalized public health services
(e.g. immunization and screening). The result section shows 14
causes of death that fulﬁlled the initial criteria, gives two examples
how these causes of death were tested in an empirical validation
analysis and presents the results of a Delphi procedure.
Methods
The AMIEHS project (Amenable Mortality in the European
Union: towards better Indicators for the Effectiveness of Health
Systems; http://amiehs.lshtm.ac.uk) has six aims, corresponding to
the six levels in the project structure in Figure 1. The outcome, a list
of indicators of amenable mortality, should provide insights into
quality of health care.
Criteria for the preliminary selection of causes of death
1. A substantial decline in mortality in a country with a well-
developed health system.
2. The cause of a sufﬁcient number of deaths so that rates are likely
to be stable over time.
3. The existence of a distinct clinical innovation of proven effec-
tiveness introduced in recent years.
Selection of the standards that must be achieved according to
each of these criteria is inevitably arbitrary. Our choice of the
magnitude of decline was 30%. We  recognized that, among those
conditions causing an appreciable number of deaths, even the best
health care system could not prevent all deaths even if a highly
effective treatment exists, so the ﬁgure should be less than 100%.
Similarly, if the death rate has fallen by only a small amount in the
presence of a generally well-performing health system, it is unlikely
that health care is currently contributing, or has the potential to
contribute much to the decline. For practical reasons a single coun-
try was  used to check this criteria that should be of sufﬁcient size to
reduce the risk of spurious results arising from small numbers, be
one where a continuous set of mortality data were available span-
ning over two  decades, and be one where any changes in coding
or other data artefacts were already known. We  ultimately chose
England and Wales. We  must then specify the time period over
which to measure any decline. Given the need to avoid problems
from coding changes, we selected the period in which ICD-9 was in
use (1979-2000). The choice of threshold for numbers of deaths
takes account of the fact that, for many EU member states, the
deaths would be likely to be substantially fewer than in England
and Wales. After discussion, a threshold of 100 has been selected.
These criteria and standards were applied to each 3-digit ICD-9
code in 1979 and 1990 in England and Wales. Some adjustments
are needed to take account of coding changes. One  is a change in
how perinatal deaths were coded; another is to include AIDS which
was not in the initial version of ICD-9 but which, it was agreed
from inspection of other data, would otherwise meet the criteria.
Another modiﬁcation was to group together the various forms of
groin hernia, each having a separate code and falling below the
threshold of 100 deaths, but clearly treated in a similar way.
Those conditions meeting the criteria were then inspected to
determine inclusion in the next step. We  excluded those that
are: a) non-speciﬁc codes, such as “other disorders of the.  . .”,
and b) conditions for which, on the basis of clinical knowledge,
no speciﬁc intervention can be identiﬁed. For the rest, a series
of systematic literature reviews was undertaken. It sought two
types of evidence. First, evidence from well conducted observa-
tional studies (typically of populations or patients attending a
facility or service) documenting a decline in mortality that could,
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with some conﬁdence, be attributed to the intervention). Sec-
ond were randomized controlled trials, again showing a decline
in mortality of 30% or more. The evidence was graded on a four
point scale: 4, evidence from systematic reviews or meta-analysis;
3, evidence from one or more randomized controlled trial; 2,
evidence from observational studies; 1, consensus statements or
expert opinions. We  excluded innovations implemented before
1970 as being of little contemporary relevance in high-income
countries.
Data collection on the timing of introduction of health care
interventions related to pre-selected causes of death
Country speciﬁc information was obtained on the year of intro-
duction and the process of diffusion within a country for each
intervention. A questionnaire was developed and distributed in
which representatives of the participating countries were asked
to identify sources of information about the introduction of these
interventions. This was answered by reference to a wide range of
data sources such as national guidelines, committee reports, scien-
tiﬁc papers, data on registration and sales of pharmaceuticals. By
combining the data within a theoretical framework of “diffusion
of innovation”17 further developed by Rogers,18,19 we determined
when we would expect a favorable change in mortality at a popu-
lation level in each country.
Validation of possible indicators of amenable mortality
by mortality trend analysis
In order to relate the timing of innovations to changes in mor-
tality a harmonized database was constructed for the period from
1970 to 2005 using mortality data from Estonia, France, Germany
(East and West separately), The Netherlands, Spain, Sweden and the
United Kingdom. This database comprises mortality data by year,
3-digit ICD-codes (revisions 8, 9 and 10), sex and 5-year age group,
that were obtained from the statistical ofﬁces of each country.
Known discontinuities due to changes in ICD-coding and recording
were reviewed. Then, a new methodology was developed, based on
the Polydect method,20 to identify abrupt changes in mortality, i.e.
“jumps”. Correction factors were applied to overcome the effect of
these changes.21
Remaining (real) discontinuities in mortality trends were sought
using joinpoint models based on linear spline regression (with
the R software), which identiﬁes “knots” where the trend changes
signiﬁcantly.22,23 This program also estimates the Percent Annual
Change (PAC) for periods between knots. This enabled trends to be
compared across countries and with the timing of introduction of
innovations. First, we studied deaths at all ages and then limited
the age range to ages from 0 to 74 in order to see in a sensitivity
analysis whether this changed the results. To choose one age cut-off
point for all causes of death is arbitrary, but we found two  standard
age limits in previous studies (65 and 75) and we choose the upper
one because of rising life expectancy and improved effectiveness of
medical treatments in higher ages. As we are interested in period
effects, prior to running the analysis any possible cohort effects
were sought by means of age-period-cohort (APC) analysis. We  ﬁrst
examined whether favorable changes in mortality trends coincide
with the period of expected mortality decline due to the introduc-
tion of a medical innovation. If a knot fell within this period, this
was deﬁned as a “match”. Inevitably, some matches will occur by
chance so we tested whether the number of matches found is signif-
icantly higher than chance. To draw a conclusion about associations
between innovations and mortality, we counted the countries that
show a match for a condition. If two thirds of all countries with
valid data show the association, we interpreted this as evidence for
an effect.
Delphi procedure
Despite taking a systematic and structured approach to the
identiﬁcation of potential indicators of amenable mortality, we rec-
ognize that a degree of judgment is still required to assess whether
the conditions were useful in practice. To incorporate this judgment
we used the Delphi method, in which individuals were asked their
view of the appropriateness of the causes identiﬁed, supplemented
by others that failed on one or a few criteria as well as conditions
that, in the judgment of the investigators, are clearly not appropri-
ate. We  included 23 individuals from 16 countries who  were either
producers or users of evidence on health systems performance,
seeking participation by both genders and health professionals and
non-health professionals. The method involved two rounds and
in each the respondents were asked to score the conditions on a
point scale (1 = inappropriate, 9 = appropriate). Following previous
research using nominal group methods to assess agreement, con-
sensus was deemed to exist when all scores (except single outliers)
were within a three point range. In the ﬁrst round, individuals were
presented with a summary, for each condition, of all information
gathered in earlier steps. In the second round they were given the
range of ﬁrst round scores, anonymized except for their own.
Electronic atlas on amenable mortality
All indicators considered at different stages of the project,
as well as indicators proposed by other projects on amenable
mortality were made publically available through an interac-
tive electronic atlas, constructed with the InstantAtlas software,
documenting variations in amenable mortality (45 causes of
death) between 31 European countries for the period 2001-2009
(http://survey.erasmusmc.nl/amiehs). Age-standardized mortality
trends are presented for males and females separately using the
European Standard Population.
Results
Figure 2 shows the stepwise selection of causes of death based
on the criteria outlined above. Of 644 three-digit ICD codes, 160
codes had 100 or more deaths in 2000 in the UK and, of those, 54
exhibited a decline in age-standardized mortality of 30% or more.
The exclusion of 40 codes for different reasons shown in Figure 2
resulted in a preliminary set of 14 conditions and 18 related inter-
ventions which are shown in Table 2 and are taken forward to
subsequent steps.
Figure 3 shows a graphical representation of the validation anal-
ysis for peptic ulcer and renal failure. In most countries mortality
from peptic ulcer (Fig. 3A) has decreased throughout the study-
period. Only for men  in France and for women in the UK there is
a positive change in mortality that falls into the expected period
of mortality decline, whereas for ﬁve countries we do not see this
association. According to our criteria this example would lead to the
conclusion that there is no sufﬁcient evidence that population level
mortality from peptic ulcer has been responsive to the introduction
of Cimetidine. Mortality trends from renal failure (Fig. 3B) are very
diverse across the countries. We  ﬁnd increasing and decreasing
trends, as well as trends that peak in the 1980s. Renal failure could
not be studied in Estonia because of incomparable ICD coding. In
the UK and Spain mortality declines in the expected period for
both men  and women. In Sweden we  see this coincidence only for
men. In three countries we do not see this match and therefore
there is no sufﬁcient evidence that population level mortality from
renal failure has been responsive to the introduction of cyclosporin.
The results of this mortality trend analysis for these two  condi-
tions serve as examples for the similar analysis of all 14 conditions
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Exceptions
N=3*
(*HIV, conditions originating in
the perinatal period (20 single
conditions), testicular cancer)
Total number of ICD-9
3-digit causes of death
N=644
Conditions that had >100
deaths in 2000
N=160
Patient- or population level evidence on
effectiveness of health care interventions
implemented after 1970
             N=14*
(*8 groups [49 single conditions]
6 individual conditions)
Exclusion:
Cause of death non-specific or
complication of disease (N=18)
No obvious health care
intervention identified (N=8)
Low improvement of survival
(N=7)
Exclusion:
Health care interventions
prior to 1970
N=7*
(*3 groups [9 single
conditions]
4 individual conditions)
Conditions with a 30% decline
in age-standardised mortality
N=54*
(*10 groups of 29 individual
conditions;
25 individual conditions)
Amalgamation of conditions
of 100 deaths/year threshold
N=3*
(*13 single conditions)
Figure 2. Flowchart illustrating the operationalisation of the desired properties of amenable mortality indicators.
Table 2
Causes of death (and related interventions) passing the selection criteria.
Condition ICD-9-code ICD-10-code Intervention
HIV 042-044 B20-B24 Antiretroviral treatment
Malign. colorectal neoplasm 153-154 C18-C21 Colonscopy
Oxaliplatin treatment
Malign. neoplasm of cervix uteri 180 C53 Introduction cervical screening
Hodgkins disease 201 C81 High dose therapy and peripheral blood stem cell
transplantation
Malign.  Neoplasm of breast 174 C50 Mammography
Tamoxifen
Malignant neoplasm of testes 186 C62 Treatment with cisplatin
Leukaemia 204-208 C91-C95 Improved treatment (or management of the disease
process and its complications for leukaemia patients
<45 years)
Rheumatic heart disease 390-398 I00-I09 Artiﬁcial valve replacement
Hypertension 401-404 I10-I13 Increased number of patients treated
Ischaemic heart disease 410-414 I20-I25 -blockers
Coronary care units
Heart failure 428-429 I50-I51 ACE inhibitors
Cerebrovascular disease 430-438 I60-I69 Treatment of hypertension
Intensive management of acute stroke (CT-scan,
thrombolytic therapy, surgical treatment of aneurysms
in subarachnoid haemorrhage)
Peptic ulcer 431-432 K25-K26 Cimetidine
Renal failure 584-586 N17-N19 Cyclosporin
204 R. Hoffmann et al. / Gac Sanit. 2013;27(3):199–206
15
20
15
10
5
0
10
5
0
10
St
an
da
rd
ise
d 
ra
te
 p
er
 1
00
,0
00
St
an
da
rd
ise
d 
ra
te
 p
er
 1
00
,0
00
St
an
da
rd
ise
d 
ra
te
 p
er
 1
00
,0
00
St
an
da
rd
ise
d 
ra
te
 p
er
 1
00
,0
00
5
0
6
4
2
0
1970 1980 1990 2000 2010 1970 1980 1990 2000
YearYear
2010
YearYear
1970 1980 1990 2000 20101970 1980 1990 2000
Estonia
UK
Germanywest
Spain
France
Sweden
Netherlands
Estonia
UK
Germanywest
Spain
France
Sweden
Netherlands
2010
UK
Germanywest
Germanywest
Spain
France
Sweden
Netherlands
Estonia
UK
Germanywest
Spain
France
Sweden
Netherlands
UK
Germanywest
Spain
France
Sweden
Netherlands
Estonia
UK
Germanywest
Spain
France
Sweden
Netherlands
Estonia UK
Germanywest
Spain
France
Sweden
Netherlands
UK
Expected periods of mortality decline based on timing of medical innovation:
Germanywest
Spain
France
Sweden
Netherlands
Expected periods of mortality decline based on timing of medical innovation:Expected periods of mortality decline based on timing of medical innovation:
Expected periods of mortality decline based on timing of medical innovation:
A B
Figure 3. A) Estimated mortality trends from peptic ulcer and expected periods of mortality decline based on the introduction of cimetidine (upper panel men; lower panel
women). B) Estimated mortality trends from renal failure and expected periods of mortality decline based on the introduction of cyclosporin (upper panel man; lower panel
women).
with similar results: overall we have not found clear evidence for
an association between innovations in health care and changes in
mortality.
Table 3 shows the results of the Delphi procedure. Only for
three conditions consensus could be reached. These were those
where all scores (except single outliers) were within a three point
range.
Discussion
The present study is based on a rigorous process of construc-
ting an up-to-date list of indicators of amenable mortality. We
demonstrate how we got from all 644 three-digit ICD-9 codes to
a preselection of 14 causes of death using explicit selection criteria.
With two example conditions we illustrate the subsequent empir-
ical validation analysis which shows that the association between
medical innovations and changes in mortality is modest. Our Del-
phi exercise shows consensus among experts on three amenable
conditions. This study uses empirical evidence to validate possible
amenable mortality indicators, whereas in the past such indica-
tors have often been selected by expert opinion only. The ﬁndings
from this project help to assess and compare the performance of
the health systems.
Some limitations need to be addressed: we focus on inno-
vations introduced after 1970. Some major innovations like the
introduction of antibiotics have taken place before and are there-
fore not considered. We  also focus on medical innovations. Yet
Table 3
Results of the Delphi procedure.
Condition Consensus
achieved
Median
score
HIV/AIDS No 7
Malignant neoplasm of rectum and colon Yes 7
Malignant neoplasm of cervix uteri Yes 7
Malignant neoplasm of the testis No 6
Hodgkin’s disease No 7
Rheumatic heart disease No 6
Hypertension No 7
Ishaemic heart disease No 7
Heart failure No 6
Cerebrovascular disease Yes 7
Peptic ulcer No 6
Renal failure No 6
Congenital heart disease No 7
Conditions originating in the perinatal period No 6
Cancer of the stomach No 5
primary cancer of the bone No 4
Leukaemia No 6
Abdominal hernias No 7
Suicide No 3
Cancer of the larynx No 4
Cancer of the female breast No 8
Diabetes No 7
Acute appendicitis No 7
Cancer of the lung, bronchus and trachea No 5
Note: a score of 1-3 indicates that the cause is considered inappropriate as an
indicator of health system performance, while that from 7-9 indicates that it is
appropriate.
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improvements in population health due to health care reﬂect three
factors: innovations, improvement in the quality with which they
are applied and expanded coverage. At the level of international
comparisons over time it is not possible to take account of the other
factors given the absence of adequate data. Third, we  are looking at
the effect of individual interventions, rather as if they are “magic
bullets”, although in reality many health gains are the consequence
of incremental improvements. Fourth, in seeking evidence of the
effect on mortality of speciﬁc innovations, we were limited as few
trials have mortality as an end point, instead using intermediate
measures. Fifth, we were constrained by the paucity of high quality
observational studies attributing health gains to particular inno-
vations. Sixth, although there is no alternative to using ICD codes
at the three digit level, they are not designed for the purpose we
are using them and the potential beneﬁts of a therapeutic innova-
tion may  be distributed among many codes, such as those related
to safer anesthesia. Finally, we adopt a narrow deﬁnition of the
health system, excluding intersectoral actions. This is inevitable if
using this method. A broader deﬁnition of the health care system
may  deﬁne more causes of death as potentially amenable. Not as a
limitation of the amenable mortality approach, but as a factor that
complicates the interpretation of observed trends in mortality, we
want to mention that many factors other than innovations in health
care inﬂuence mortality. Given the difﬁculty in precisely measur-
ing these factors, it will remain a challenge to interpret mortality
changes on the population level as a consequence of the particu-
lar change in health care. Socioeconomic differences in the trends
of mortality and in the diffusion of medical innovation may  hide
socioeconomic differences in amenability. This could not be taken
into account in this study. A recent study suggests that socioeco-
nomic differences in amenable mortality do not reﬂect differences
in access or quality of care.24
In the AMIEHS project the concept of amenable mortality is
addressed in a completely different manner from previous studies
by starting from all causes of death and working down to a limited
number. Secondly, our selection of indicators is linked directly to
changes in health care practice, addressing a previous criticism
of the concept of amenable mortality. The indicators we  identi-
ﬁed help to highlight shortcomings in health care, but mortality
rates from amenable causes must be used with caution as indi-
cators of health care effectiveness in international comparisons.
What is known on the topic?
There is widespread consensus on the need for better indi-
cators of the effectiveness of health care. This gave rise to the
concept of ‘avoidable’ or ‘amenable’ mortality in the 1970s.
However, the validity of certain causes of death as indicators
of the effectiveness of health care has never been formally and
systematically demonstrated.
What does this study add to the literature?
The innovation developed in the project “Amenable mor-
tality in the European Union: towards better indicators for
the effectiveness of health systems” (AMIEHS) is a rigor-
ous new approach to the concept of amenable mortality that
includes empirical validation. We  describe the study design,
discuss our selection criteria, list 14 causes of death passing
these criteria, and present two examples of the empirical vali-
dation that assessed whether the introduction of innovations
in health care coincided with declines in mortality from poten-
tially amenable causes in seven European countries.
Elsewhere we suggest two possible alternative measures of
amenable mortality25 and more in-depth analyses will be needed to
identify the speciﬁc failures in health care systems. For policy mak-
ers the indicators identiﬁed in this study will offer the opportunity
to put extra attention into speciﬁc causes of death. For researchers
these indicators are hotspots giving rise to new investigations in
the future.
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